Search
Biodesix Inc
BDSXAdd to Watchlist
14.170USD
-0.590-4.00%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
143.24MMarket Cap
LossP/E TTM
More Details of Biodesix Inc Company
Biodesix, Inc. is a diagnostic solutions company. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Biodesix Inc Info
Ticker SymbolBDSX
Company nameBiodesix Inc
IPO dateOct 28, 2020
CEOHutton (Scott)
Number of employees273
Security typeOrdinary Share
Fiscal year-endOct 28
Address919 West Dillon Road
CityLOUISVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80027
Phone13034170500
Websitehttps://www.biodesix.com/
Ticker SymbolBDSX
IPO dateOct 28, 2020
CEOHutton (Scott)
Company Executives of Biodesix Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
375.81K
+0.36%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
152.98K
-0.00%
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
18.17K
-0.01%
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
17.88K
-0.01%
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
17.14K
+8.24%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
10.12K
+6.05%
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Independent Director
Independent Director
5.41K
-0.02%
Mr. Scott Hutton
Mr. Scott Hutton
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Lawrence T. (Lair) Kennedy, Jr.
Mr. Lawrence T. (Lair) Kennedy, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Patience
Mr. John Patience
Independent Chairman of the Board
Independent Chairman of the Board
375.81K
+0.36%
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
152.98K
-0.00%
Mr. Hany Massarany
Mr. Hany Massarany
Independent Director
Independent Director
18.17K
-0.01%
Dr. Jon Faiz Kayyem, Ph.D.
Dr. Jon Faiz Kayyem, Ph.D.
Independent Director
Independent Director
17.88K
-0.01%
Ms. Robin Harper Cowie
Ms. Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
17.14K
+8.24%
Mr. Kieran O'Kane
Mr. Kieran O'Kane
Chief Commercial Officer
Chief Commercial Officer
10.12K
+6.05%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
By BusinessUSD
Name
Revenue
Proportion
Lung Diagnostic Testing
79.20M
89.49%
Development Services
9.30M
10.51%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Lung Diagnostic Testing
79.20M
89.49%
Development Services
9.30M
10.51%
Shareholding Stats
Updated: Wed, May 13
Updated: Wed, May 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Schuler (Jack W)
22.88%
Kennedy (Lawrence T Jr.)
12.59%
AIGH Capital Management, LLC.
5.47%
Soleus Capital Management, L.P.
4.95%
Telemark Asset Management, LLC
4.85%
Other
49.27%
Shareholders
Shareholders
Proportion
Schuler (Jack W)
22.88%
Kennedy (Lawrence T Jr.)
12.59%
AIGH Capital Management, LLC.
5.47%
Soleus Capital Management, L.P.
4.95%
Telemark Asset Management, LLC
4.85%
Other
49.27%
Shareholder Types
Shareholders
Proportion
Individual Investor
42.17%
Investment Advisor
11.38%
Hedge Fund
7.47%
Private Equity
6.54%
Investment Advisor/Hedge Fund
5.24%
Corporation
1.08%
Research Firm
0.28%
Other
25.85%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
111
3.03M
29.99%
+290.07K
2025Q4
106
1.44M
36.52%
--
2025Q3
107
1.45M
36.66%
-344.58K
2025Q2
107
1.79M
45.09%
-888.44K
2025Q1
105
2.68M
48.65%
-880.49K
2024Q4
100
2.95M
44.33%
-176.20K
2024Q3
93
3.13M
37.31%
+438.60K
2024Q2
96
2.69M
15.79%
+1.57M
2024Q1
114
820.05K
16.77%
+5.46K
2023Q4
112
794.09K
17.61%
-6.06K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Schuler (Jack W)
2.31M
23.46%
+182.47K
+8.56%
Jan 23, 2026
Kennedy (Lawrence T Jr.)
1.27M
12.91%
+5.31K
+0.42%
Mar 03, 2025
Soleus Capital Management, L.P.
500.00K
5.07%
+500.00K
--
Jan 12, 2026
Telemark Asset Management, LLC
427.82K
4.34%
+100.00K
+30.50%
Jan 22, 2026
abrdn Inc.
262.43K
2.66%
+262.43K
--
Dec 31, 2025
Patience (John)
374.46K
3.8%
+1.14K
+0.31%
Jan 05, 2026
Strobeck (Matthew W)
152.98K
1.55%
--
--
Mar 03, 2025
Birchview Capital, LP
286.80K
2.91%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Sep 11, 2025
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Sep 11, 2025
Merger
20→1
